Machine learning models predict release profile to accelerate drug development
Machine learning models have predicted the drug release profiles of long-acting injectable medicines, suggesting that the algorithms can accelerate the development of a promising class of therapies. Read More
Wyss Institute launches RNA therapeutics startup EnPlusOne Biosciences
Wyss Institute at Harvard University has partnered with Northpond Labs to launch EnPlusOne Biosciences. The startup aims to bring versatile, scalable RNA synthesis technology to market, with the goal of unlocking the development of new RNA drugs, vaccines, and gene-editing therapies. Read More
Functional genomics reveals gateway to intracellular targets for large molecules
Complementary genome-scale, chemical-genetic approaches have revealed a cellular gateway that could allow large molecules to enter cells, providing new opportunities to develop drugs for intracellular targets, according to University of California San Francisco (UCSF) researchers. Read More
New research shows smallpox vaccine trains T cells to recognize mpox
Scientists from the La Jolla Institute for Immunology have found new evidence that the vaccinia vaccine MVA-BN (brand name JYNNEOS) can train virus-fighting T cells to recognize the monkeypox (mpox) virus. Read More
Study offers researchers more reliable way to design effective CELMoD drugs
Scripps Research scientists have discovered a key property needed for a promising new class of cancer-fighting drugs -- known as Cereblon E3 Ligase Modulating Drugs (CELMoDs) -- to work effectively as protein degraders. Read More
Challenge to textbook model of GPCR-mediated signaling opens door to new therapies
University of California, San Diego researchers have challenged the textbook model of how G protein-coupled receptors (GPCRs) mediate signaling in a study that could change how drugs against widely pursued targets are developed, including multiple forms of cancer. Read More
EGFR-targeting cell penetrating peptide treats triple-negative breast cancer in mice
A cell penetrating peptide designed to mimic an epidermal growth factor receptor (EGFR) binding domain has induced tumor regression in mice, opening up a new avenue of research into the treatment of triple-negative breast cancer. Read More
Unlocking New Research Frontiers with Ultra-Sensitive Epigenomics
On-Demand Webinar -- By using a novel in situ strategy that enables unprecedented mapping sensitivity and simplified workflows, CUT&RUN and CUT&Tag are creating a paradigm shift in epigenomics research. Andrea Johnstone, PhD, senior director for product development at EpiCypher, illustrates how these scalable technologies unlock the full potential of epigenomics for next-generation chromatin studies. Read More
GenNext wins $250K grand prize at 2022 BioTools Innovator capstone event
GenNext Technologies, a growth-stage company that enables analysis of protein higher order structure to improve and accelerate drug discovery development, won a $250,000 grand prize at the 2022 BioTools Innovator capstone event on October 13 in Carlsbad, CA. Read More
Stanford team synthesizes anticancer compound currently only sourced from rainforest tree
The synthesis of an anticancer compound in the laboratory by Stanford University researchers has cleared a barrier to the widespread use of a drug candidate that is currently extracted from a single plant species. Read More
Conferences
Science Briefs
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Connect
